CTLA4 and melanoma: Snyder et al. characterized the exomes of malignant melanoma cells from patients that had received immunotherapy blocking CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), which functions as an immune checkpoint and downregulates immune responses.